Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a new toothpaste tame gum disease by keeping good bacteria happy?

NCT ID NCT07397312

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This pilot study tests a new toothpaste designed to protect the natural balance of bacteria in the mouth. 28 adults with periodontitis will brush twice daily for 3 months while continuing their usual gum disease care. Researchers will check if the toothpaste improves oral health compared to before use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
microbiome-modulating toothpaste
What this could lead to
If it works, this could point toward a simple daily toothpaste that helps control gum disease by supporting a healthy mouth microbiome.
What could go wrong
This is a very small pilot study (28 people) with no blinding or placebo control, so results may not be reliable or generalizable. The toothpaste is a cosmetic product, not a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. * Good general health with no clinically significant and relevant abnormalities of medical history. * Absence of any condition that would impact on the subject's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements. At Screening (Visit 1): * Participant with at least 16 natural, permanent teeth. * A participant who gets regularly professional tooth cleaning in a frequence of once to twice yearly. * Participant whose biofilm contains at least Porphyromonas gingivalis. Exclusion Criteria: * A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a sponsor's employee directly involved in the conduct of the study or a member of their immediate family. * A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation. * A participant with an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study. * A participant who has any other clinical serious or unstable conditions (for example, cardiovascular diseases, diabetes, liver disorders, bleeding disorders, and kidney disorders) which could have affected study outcomes and/or participant safety. * A participant who plans to get pregnant during the study or is already pregnant (pregnancy testing) or breastfeeding. * A participant who is known or suspected of intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. * A participant who is unwilling or unable to comply with the lifestyle considerations. * Participant who is a current smoker (more than 10 cigarettes per day). * Participant who is using smokeless forms of tobacco (for example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes). * A participant who is diagnosed with xerostomia or is taking any medication that is causing xerostomia. * A participant who has a recent history (within the last year) of alcohol or other substance abuse. * A participant who has a severe oral condition (for example, necrotizing gingivitis/periodontitis or oral or peri-oral ulceration) that could compromise study outcomes or the oral health of the participant/examiner if they participate in the study. * A participant who has previously been enrolled in this study. Medication exclusions at screening (Visit 1): * A participant who is using any antibiotic medication within 3 months prior to inclusion or at any time during the study. * A participant who is currently taking an anti-inflammatory or systemic medication (for example, immunosuppressants), which could affect plaque/gingival condition (for example, ibuprofen, aspirin, cyclosporin, phenytoin, calcium channel blockers) repeatedly for more than 3 consecutive days within study participation. Periodontal and dental exclusions: * A participant who has a formally untreated or not controlled periodontitis. * A participant who has active caries that could compromise study outcomes or the oral health of the participant if they participate in the study. * A participant who has an orthodontic appliance (bands, appliances, or fixed/ removable retainers except night guards). * A participant who has any dental condition (for example, overcrowding) that could compromise study outcomes or the oral health of the participant if they participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Periodontitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    4 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dr. G. Jungbauer

    RECRUITING

    Straubing, 94315, Germany

  • Dr. Hofmann

    ACTIVE_NOT_RECRUITING

    Bietigheim-Bissingen, 74321, Germany

  • Dr. T. Schütz

    RECRUITING

    Borna, 04552, Germany

  • Universitätspoliklinik für Zahnerhaltungskunde und Parodontologie

    RECRUITING

    Halle, Saxony-Anhalt, 06112, Germany

  • Zahnzentrum Halle

    RECRUITING

    Halle, Saxony-Anhalt, 06114, Germany

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.